tbuckley/cabot-search huggingface dataset:
Evaluation of serum CXCL5 as a serum marker for prognosis of colorectal cancer patients.
Authors: M. Kawamura, Y. Toiyama, K. Tanaka, H. Yasuda, H. Fujikawa, S. Saigusa, Y. Inoue, C. Miki, M. Yamaguchi, M. Kusunoki
Journal: Journal of Clinical Oncology (2011)

442 Background: CXCL5 is known as CXC chemokine which promotes angiogenesis related to cancer. However, the function of serum level of CXCL5 (sCXCL5) has not been fully studied in colorectal cancer. The purpose of this study was to evaluate the relationships between preoperative sCXCL5 and clinicopathological features and prognosis in colorectal cancer. Methods: This was a single-institution, retrospective study. Preoperative serum samples of 250 colorectal cancer patients (between 1998 and 2007, median age: 65.3 years, male 159/female 91) were available for the study, and 33 normal serum was examined and used as a control. sCXCL5 level was assayed using a commercially available enzyme-linked immunosorbent assay kit, and analyzed statistically. Results: Mean level of sCXCL5 was significantly higher in colorectal cancer patients than in control group (p=0.013). Patients with liver metastases had significantly higher sCXCL5 level than those without metastases (p=0.0086), and in logistic analysis, sCXCL5 was an independent marker for predicting liver metastasis (p=0.040). Overall survival of patients with elevated sCXCL5 level was significantly worse than those with lower sCXCL5 (p=0.0006). Conclusions: Preoperative sCXCL5 level was increased in colorectal cancer patients compared to in healthy volunteer and elevated sCXCL5 was correlated with liver metastasis and poor prognosis for overall survival in colorectal cancer patients. Elevated sCXCL5 has been proposed as a useful predictive marker for liver metastasis and overall survival in colorectal cancer. No significant financial relationships to disclose.
Systematic pain evaluation in hospitalized cancer patients in a Medical Oncology Unit: feasibility and utility of pain monitoring by Numeric Rating Scale in cancer pain management
Authors: R. Magarotto, B. Micheloni, G. Lunardi, S. Duranti, A. Inno, M. Valerio, M. Bustaggi, S. Castagna, A. Dalle Vedove, M. Duma, L. Mignolli, L. Oliosi, M.C. Platano, G. Residori, P. Righetti, A. Ronconi, C. Unguru, S. Zivelonghi, S. Gori
Journal: Annals of Oncology (2016)
Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.
Authors: Felipe Samaniego, Jillian F Wise, Rong-Hua Tao, Haifeng Zhu, Xue Ao, Zeming Chen, Wenzhuo Zhuang, Frank K Braun, Rohit Mathur, Jorge Enrique Romaguera, Luis Fayad, Michael Wang, Peter McLaughlin, Timothy J. McDonnell, Keyur P. Patel, Sattva S. Neelapu, Larry W. Kwak, Zuzana Berkova
Journal: Blood (2012)
Quinine-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Characteristic Clinical Presentation and High Risk for Chronic Kidney Disease (CKD)
Authors: Cassandra C Deford, Jessica A Reese, Zayd Al-Nouri, Deirdra Terrell, Sara K. Vesely, James N. George
Journal: Blood (2011)
Trisomy of Chromosome #13 in Spontaneous Mammary Tumors of GR, C3H, and Noninbred Swiss Mice
Authors: Jack Spira
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Trisomy of Chromosome #13 in Spontaneous Mammary Tumors of GR, C3H, and Noninbred Swiss Mice Get access Jack Spira Jack Spira Department of Tumor Biology Karolinska Institutet Stockholm, Sweden Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 65, Issue 4, October 1980, Page 668, https://doi.org/10.1093/jnci/65.4.668 Published: 01 October 1980
High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.
Authors: Oliver Weigert, Eckhart Weidmann, Rudolf Mueck, Martin Bentz, Christoph von Schilling, Robert Rohrberg, Kathleen Jentsch-Ullrich, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2006)
Is Deep-Vein Thrombosis Always the Origin of Pulmonary Embolism? Imaging of Veins with a Total-Body Direct Thrombus MRI Technique
Authors: Kirsten van Langevelde, Alexandr Srámek, Patrice W.J. Vincken, Jan-Kees van Rooden, Frits R. Rosendaal, Suzanne C. Cannegieter
Journal: Blood (2011)
Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials
Authors: M. Clavarezza, M. Puntoni, A. Gennari, L. Paleari, N. Provinciali, M. D'Amico, A. Decensi
Journal: Annals of Oncology (2016)
Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).
Authors: Alireza Eghtedar, Hagop Kantarjian, Elias Jabbour, Susan O'Brien, Alfonso Quintas-Cardama, Elizabeth Burton, Guillermo Garcia-Manero, Srdan Verstovsek, Marina Konopleva, Jorge E. Cortes
Journal: Blood (2010)
Incidence and Spectrum of MLL Gene Rearrangements in Pediatric Acute Leukemias in Poland
Authors: Tomasz Szczepanski, Anna Gaworczyk, Claus Meyer, Joanna Bulsa, Iwona Malinowska, Maciej Niedzwiecki, Olga Haus, Andrzej Koltan, Katarzyna Derwich, Marek Ussowicz, Lilianna Chelmecka-Hanusiewicz, Katarzyna Muszynska-Roslan, Igor Olejnik, Grazyna Sobol, Joanna Trelinska, Grazyna Karolczyk, Elzbieta Kamienska, Danuta Sonta-Jakimczyk, Dorota Winnicka, Jerzy Kowalczyk, Michal Matysiak, Wanda Trautsolt, Eric Kowarz, Rolf Marschalek
Journal: Blood (2008)
Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML
Authors: Nathalie Droin, Raphael Itzykson, Philippe Rameau, Margot Morabito, Thorsten Braun, Fawzia Louache, Yanyan Zhang, Stephane De Botton, Catherine Cordonnier, Bruno Quesnel, Pierre Fenaux, William Vainchenker, Eric Solary
Journal: Blood (2010)
IMST-35. IDO1 AND TARGETED IMMUNOTHERAPY IN A MOUSE GLIOBLASTOMA MODEL
Authors: Erik Ladomersky, Lijie Zhai, Galina Gritsina, Kristen Lauing, Matthew Genet, Orin Bloch, C. David James, Derek Wainwright
Journal: Neuro-Oncology (2016)

A diagnosis of Glioblastoma (GBM) has remained fatal even after maximum surgical resection, radiotherapy (RT), and chemotherapy, with a median overall survival (OS) of 14.6 months. Combinatorial treatment approaches addressing both tumor growth and the potent immunosuppression may prove to be more effective than current immunotherapies. This work aimed to determine the efficacy of novel, pharmaceutical-grade small molecule inhibitor of IDO1, BGB-5777, in combination with PD-1 blockade and/or whole brain radiation in an immunocompetent mouse glioblastoma model. All mice were intracranially-engrafted 2 × 105 GL261 cells to recapitulate brain tumors. At 14 days post-intracranial injection, mice were treated with 2Gy RT for 5 days (n=8), 500ug dose, followed by three 200ug doses given every 3 days, of PD-1 mAb (J43) (n=8), or 100mg/kg BGB-5777 for 4 weeks (n=10), with a median OS of 25, 32, and 26.5days, respectively. Mice treated with dual therapies including RT and PD-1 mAb (n=10), RT and BGB-5777 (n=8), or PD-1 mAb and BGB-5777 (n=9), had a median OS of 30, 39, and 32days, respectively. All mice treated with mono- or dual-therapy succumbed to tumor burden. In contrast, mice treated with concurrent RT, PD-1 mAb and BGB-5777 (n=9) showed a significant increase in median OS to 53 days (P<0.0001) with 33% of mice demonstrating a durable survival benefit (>150 days). Importantly, mice treated with the triple therapy and co-administered CD4 (n=9)-, but not CD8 (n=9)- or NK1.1 (n=9)-depleting mAb, significantly decreased median OS to 29 days (P>0.001) confirming the requirement of CD4+T cells for efficacy of this immunotherapeutic approach. The data indicate that combining RT, with PD-1 blockade and the novel IDO1 inhibitor, BGB-5777, synergistically increases OS in a mouse GBM model. Ultimately, these data suggest that using radiation to induce potential immunogenicity and/or inflammation in GBM, while co-inhibiting immunosuppression, is a rational and potentially clinically-beneficial pursuit.
Robert P C MacDonald
Authors: John Tilley
Journal: BMJ (2017)

Robert P C MacDonald (“Dr Mac”) was a GP on the Hoo Peninsula, where he joined his brother in law, Bob Tilley, who had taken on a small practice in 1947. The practice served a wide area of rural communities on the bracing saltings and mudflats made famous by the writer Charles Dickens around the Isle of Grain, where in the mid-1950s BP decided to site a large oil refinery. This development made for a vast increase in activity and population growth, and provided an opportunity for Dr Mac to establish a visionary practice. He built a large health centre and new day centre in Hoo, and expanded a small surgery (originally a caravan) into five large peripheral surgeries. His was one of the …
Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia
Authors: Ailsa Holroyd, Elizabeth Phillips, Richard Szydlo, David Marin, Letizia Foroni, Jamshid Khorashad, Dragana Milojkovic, Edward J. Kanfer, Francesco Dazzi, Donald H. MacDonald, Amin Rahemtulla, Donal McLornan, Ian H Gabriel, Jiri Pavlu, Jeremy Sargent, John M. Goldman, Jane F. Apperley, Katayoun Rezvani
Journal: Blood (2010)
Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma
Authors: J. Tabernero, J.R. Infante, A. Mita, C. Keung, D. Skee, H. Xie, T. Parekh, P. De Porre, F.R. Luo, J.-C. Soria
Journal: Annals of Oncology (2016)
Polymorphism of CDH1 Promoter Is a Predictor of Clinical Outcome in Patients with Metastatic Gastric Cancer Treated with chemotherapy
Authors: A. Buonadonna, L. caggiari, A. de paoli, R. cannizzaro, G. miolo, V. canzonieri, E. torrisi, G. Lo Re, G. aprile, M. bonotto, G. cardellino, G. bertola, C. belluco, G. boz, G. tabaro, V. de re
Journal: Annals of Oncology (2016)
The NLRP3 Inflammasome Has a Critical Role in Peritoneal Dialysis-Related Peritonitis
Authors: Nicolas Hautem, Johann Morelle, Amadou Sow, Cyril Corbet, Olivier Feron, Eric Goffin, François Huaux, Olivier Devuyst
Journal: Journal of the American Society of Nephrology (2017)

Bacterial peritonitis remains the main cause of technique failure in peritoneal dialysis (PD). During peritonitis, the peritoneal membrane undergoes structural and functional alterations that are mediated by IL-1 β . The NLRP3 inflammasome is a caspase-1–activating multiprotein complex that links sensing of microbial and stress products to activation of proinflammatory cytokines, including IL-1 β . The potential roles of the NLRP3 inflammasome and IL-1 β in the peritoneal membrane during acute peritonitis have not been investigated. Here, we show that the NLRP3 inflammasome is activated during acute bacterial peritonitis in patients on PD, and this activation associates with the release of IL-1 β in the dialysate. In mice, lipopolysaccharide- or Escherichia coli -induced peritonitis led to IL-1 β release in the peritoneal membrane. The genetic deletion of Nalp3 , which encodes NLRP3, abrogated defects in solute transport during acute peritonitis and restored ultrafiltration. In human umbilical vein endothelial cells, IL-1 β treatment directly enhanced endothelial cell proliferation and increased microvascular permeability. These in vitro effects require endothelial IL-1 receptors, shown by immunofluorescence to be expressed in peritoneal capillaries in mice. Furthermore, administration of the IL-1 β receptor antagonist, anakinra, efficiently decreased nitric oxide production and vascular proliferation and restored peritoneal function in mouse models of peritonitis, even in mice treated with standard-of-care antibiotherapy. These data demonstrate that NLRP3 activation and IL-1 β release have a critical role in solute transport defects and tissue remodeling during PD-related peritonitis. Blockade of the NLRP3/IL-1 β axis offers a novel method for rescuing morphologic alterations and transport defects during acute peritonitis.
Neoadjuvant Chemotherapy among Breast Cancer subtypes: a single-institution retrospective study
Authors: I. Ferrarini, A. Fontana, I. Bertolini, L. Diodati, C. De Angelis, I. Montagnani, B. Salvadori, M. Ghilli, E. Landucci, M. Lo Russo, E. Pfanner, E. Rossetti, P. Ferrari, L. Fustaino, A. Michelotti, M. Roncella, A. Falcone
Journal: Annals of Oncology (2016)
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
Authors: O. Hamid, I. Puzanov, R. Dummer, J. Schachter, A. Daud, D. Schadendorf, C. Blank, L.D. Cranmer, C. Robert, A.C. Pavlick, R. Gonzalez, F.S. Hodi, P.A. Ascierto, A. Salama, K.A. Margolin, T.C. Gangadhar, Z. Wei, S.W. Ebbinghaus, N. Ibrahim, A. Ribas
Journal: Annals of Oncology (2016)

In KEYNOTE-002 (NCT01704287), pembro provided superior PFS over investigator-choice chemo in patients (pts) with advanced melanoma and confirmed progression after ≥2 ipi doses (HR 0.57, P < .0001 for 2 mg/kg Q3W and HR 0.50, P < .0001 for 10 mg/kg Q3W). We present the final OS. 540 pts were randomized to pembro 2 mg/kg Q3W (n = 180) or 10 mg/kg Q3W (n = 181) or to 1 of 5 chemo regimens (n = 179). Pembro was given until disease progression or intolerable toxicity. Chemo was given per standard practice. Pts in the chemo arm who progressed could crossover to pembro. Response (RECIST v1.1, central review) was assessed at wk 12, every 6 wk until wk 48, then every 12 wk. Primary end points were OS and PFS. Final analysis was to be done at 370 deaths. OS differences were assessed in the ITT population using the stratified log-rank test with the Hochberg procedure; OS was positive if P was < .01 for 1 pembro arm. As of Nov 16, 2015, median follow-up was 13.5 mo and 368 deaths had occurred. Median OS was 13.4 mo for 2 mg/kg, 14.7 mo for 10 mg/kg, and 11.0 mo for chemo. 18-mo OS rates were 40%, 44%, and 36%; 24-mo rates were 36%, 38%, and 30%. HR (95% CI) for OS was 0.86 (95% CI 0.67-1.10) for 2 mg/kg (P = .1173 ) and 0.74 (0.57-0.96) for 10 mg/kg (P = .0106), with no difference between doses (0.87 [95% CI 0.67-1.12]). When the 98 (55%) pts in the chemo arm who crossed over were censored at crossover, HR (95% CI) was 0.79 (0.58-1.08) for 2 mg/kg (P = .0683) and 0.67 (0.49-0.92) for 10 mg/kg (P = .0068), again with no difference between doses (0.87 [95% CI 0.67-1.12]). 24-mo PFS rates were 16% for 2 mg/kg, 22% for 10 mg/kg, and <1% for chemo. ORR was 22%, 28%, and 4%; 73%, 74%, and 13% of responders had no progression at analysis. Grade 3-5 drug-related AE rates remained lower with pembro (13% and 17% vs 26%) despite longer exposure (mean 232 d and 276 d vs 82 d). Pembro prolonged OS over chemo for ipi-refractory melanoma; with a 55% crossover rate, the difference did not reach statistical significance for either pembro dose. Coupled with the significant PFS benefit, durable responses, and lower rate of high-grade drug-related AEs, these data support pembro as a standard of care for this population.
A “Single” Dose of G-CSF after Autologous Stem Cell Transplantation in Patients with Malignant Lymphoma - Third Interim Analysis of Multicentre Randomized Trial Comparing Standard Schedule with Delayed Application and Placebo.
Authors: Edgar Faber, Robert Pytlik, Marek Trneny, Jiri Slaby, Tomas Kozak, Ludek Raida, Tomas Papajik, Eva Zikesova, Jana Zapletalova, Ivana Maresova, Michaela Hamouzova, Karel Indrak
Journal: Blood (2004)
BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
Authors: Irene Slavc, Andreas Peyrl, Amedeo A. Azizi, Johannes Gojo, Dominik Reisinger, Chryssa Grylli, Monika Chocholous, Christine Haberler, Thomas Czech
Journal: Neuro-Oncology (2016)

Embryonal brain tumors carry a high risk for leptomeningeal dissemination and tumor cells floating in the CSF are often not amenable to systemic and/or antiangiogenic chemotherapy. We report on our experience with an intraventricular therapy consisting of alternating cycles of liposomal cytarabine and etoposide. Between 2005 and 2015, 57 patients aged 0.6 to 23 years (median 8 years) with various malignant brain tumors received intraventricular etoposide 0.25mg (<1year) - 0.5mg on five consecutive days alternating with liposomal cytarabine at a dose of 25mg (<3 years) - 50mg via an Ommaya reservoir. 3797 doses of etoposide (5-277/patient) corresponding to 1-56 five-day-cycles/patient (median 10) with a cumulative dose of 2.5 – 138.5 mg/patient (median 25.5mg) alternating with 398 doses of liposomal cytarabine (1-20/patient, median 6) with a cumulative dose of 25-905mg/patient (median 225mg) were administered. Treatment was given over a period of 1 – 98 monhts (median10). Toxicities such as mild to moderate transient headaches and nausea were more frequent after liposomal cytarabine (20 versus4). Twelve patients receiving liposomal cytarabine developed increased intracranial pressure requiring evacuating lumbar puncture, three experienced transient decline in short term memory, two developed a hearing deficit and one a transient visual impairment. Since all patients received some sort of concurrent anti-cancer therapy, the efficacy of intrathecal therapy cannot be assessed independently. However, 32/57 patients are still alive and only 6/25 patients who died had developed metastases, 19 died of local recurrences, and none had tumor cells in the CSF at their last evaluation. In conclusion, alternating intraventricular liposomal cytarabine and etoposide is feasible, allows for a more dose tense schedule, may produce responses and prove to be an important adjunct for patients receiving drugs with a low penetrance into the CSF.
Large CD45 Protein Tyrosine Phosphatase (PTP) Isoforms Predominate in Myelodysplastic Erythroid Precursors and Attenuate the Erythropoietin (EPO): STAT5 Signal.
Authors: Alan List, M. Estes, G. Gao, A. Janokowska, J. Maciejewski
Journal: Blood (2006)
FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer
Authors: Gary A. Ulaner, Alexandra M. Zindman, Junting Zheng, Tae Won B. Kim, John H. Healey
Journal: Clinical Nuclear Medicine (2017)

Purpose Assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation to prevent pathological fractures. Better prediction of pathological fracture risk is needed. We evaluated if quantitative measures of FDG avidity can assess femoral pathological fracture risk in patients with metastatic breast cancer (MBC). Patients and Methods A Health Insurance Portability and Accountability Act–compliant retrospective case-control study was performed under institutional review board waiver. Patients with MBC who received an FDG PET/CT from January 2008 to December 2014 and had pathological fracture of the proximal femur within 3 months of PET/CT were selected as cases. Patients with MBC who had an FDG PET/CT in 2013 were sequentially screened in reverse chronological order to identify patients with proximal femoral metastases on PET/CT but no subsequent pathological fracture to serve as a control group. The prespecified goal was to have twice the number of controls as cases. Target lesions in the proximal femur, from femoral head to 5 cm below the lesser trochanter, were analyzed on FDG PET/CT for SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis. Wilcoxon rank sum test was used to compare continuous variables in cases and controls. A nonparametric receiver operating characteristic analysis was performed to assess the ability of quantitative FDG measurements to differentiate between cases and controls. Results In 27 cases with pathological fracture and 55 controls without pathological fracture, all 4 quantitative measures of FDG avidity were statistically different between cases and controls (P < 0.001). A total lesion glycolysis of 81 could differentiate between fracture and nonfracture patients with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. Conclusions Quantitative measures of FDG avidity may help identify breast cancer patients at high risk of subsequent pathological fracture of the proximal femur.
IMST-34. IMMUNOLOGICAL CHANGES DURING TUMOR PROGRESSION FROM PRIMARY TO RECURRENT GLIOBLASTOMA
Authors: Christel Herold-Mende, Carmen Rapp, Rolf Warta, Steffen Dettling, Andreas von Deimling, Andreas Unterberg
Journal: Neuro-Oncology (2016)

Frequently novel therapies such as immunotherapy are developed based on knowledge obtained from primary glioblastoma (pGBM), but are then also applied to treat recurrent tumors (rGBM). However, knowledge about expression changes, immunological changes and adaptations of the tumor microenvironment during GBM progression is still limited. Therefore, we performed a comprehensive analysis of pGBM and corresponding rGBM tissues of 60 patients regarding changes in the transcriptome, their immunogenicity and intratumoral immune cell infiltration. Multi-color-immunofluorescent stainings and subsequent objective evaluation showed a significant accumulation of immunosuppressive M2-polarized microglia cells in recurrent tumors. These changes have been accompanied by a concomitant decrease of immune-relevant chemokines and cytokines as determined by Luminex analyses. On the other side, an age-dependent increase of CD8+ effector T cells was observed during tumor progression in association with a better survival. Subsequent microarray analyses revealed marked changes on the transcriptome level occurring from pGBM to rGBM suggesting unbeneficial tumor cell selection processes. To finally identify immunogenic antigens as well as changes in the immunogenic repertoire between pGBM and rGBM, a combination of protein fractionation (PF2D) and T cell activation assays (IFN-γ ELISpot Assay) was employed. In most of the patients severe changes regarding the spontaneous recognition of distinct protein fractions were observed. However, out of 1500 proteins identified by mass spectrometry to be present in immunogenic protein fractions of pGBM and rGBM, we recognized four immunogenic proteins to show frequent spontaneous T cell responses in glioblastoma patients but not in healthy donors. Overexpression of these proteins and an inverse relation to survival strengthen their suitability as vaccine antigens for future immunotherapies not only in pGBM but also in rGBM. Altogether our analysis might help to select for patients who are suited for immunotherapy even at the time of recurrence and to select for promising vaccine antigens in this setting.
The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL
Authors: Dan A. Landau, Clare Sun, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, Julia Hoellenriegel, Mohammed Farooqui, Wandi Zhang, Donna S. Neuberg, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, Jan Burger, Adrian Wiestner, Catherine J Wu
Journal: Blood (2016)